- $3.45bn
- $3.08bn
- $379.81m
CareDx Inc reports results for the quarter ended in January - Earnings Summary
Brief: CareDx Q2 Adjusted EPS USD 0.25 Vs. IBES Estimate USD -0.14
CareDx Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Caredx Reiterates Position That It Does Not Infringe The ‘544 Patent, Injunction Motion Is Irrelevant
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings
CareDx Inc reports results for the quarter ended in March - Earnings Summary
Brief: CareDx Q1 Adjusted EPS USD -0.03 Vs. IBES Estimate USD -0.21
CareDx Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Caredx Appoints John Hanna As Its New President And CEO
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed (updated)
Brief: Caredx Appoints Bryan Riggsbee To Its Board Of Directors
CareDx Inc reports results for the quarter ended in December - Earnings Summary
Brief: CareDx Q4 Adjusted EPS USD -0.17 Vs. IBES Estimate USD -0.27
CareDx Inc expected to post a loss of 27 cents a share - Earnings Preview
CareDx Inc expected to post a loss of 27 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Sarepta, Hershey, Dollar Tree
U.S. STOCKS ON THE MOVE-Overseas Shipholding, Palisade Bio, Archer-Daniels-Midland
CareDx owes Natera $96 mln in genetic-testing patent case, US jury says
CareDx down after jury awards peer Natera $96 mln in patent trial